JP2021527137A5 - - Google Patents

Info

Publication number
JP2021527137A5
JP2021527137A5 JP2021518994A JP2021518994A JP2021527137A5 JP 2021527137 A5 JP2021527137 A5 JP 2021527137A5 JP 2021518994 A JP2021518994 A JP 2021518994A JP 2021518994 A JP2021518994 A JP 2021518994A JP 2021527137 A5 JP2021527137 A5 JP 2021527137A5
Authority
JP
Japan
Prior art keywords
group
rpn11
nhme
sme
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021518994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/065481 external-priority patent/WO2019238817A1/en
Publication of JP2021527137A publication Critical patent/JP2021527137A/ja
Publication of JP2021527137A5 publication Critical patent/JP2021527137A5/ja
Pending legal-status Critical Current

Links

JP2021518994A 2018-06-13 2019-06-13 Rpn11を標的化するための二機能性分子 Pending JP2021527137A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862684265P 2018-06-13 2018-06-13
US62/684,265 2018-06-13
US201962835953P 2019-04-18 2019-04-18
US62/835,953 2019-04-18
PCT/EP2019/065481 WO2019238817A1 (en) 2018-06-13 2019-06-13 Bifunctional molecules for targeting rpn11

Publications (2)

Publication Number Publication Date
JP2021527137A JP2021527137A (ja) 2021-10-11
JP2021527137A5 true JP2021527137A5 (cg-RX-API-DMAC10.html) 2022-06-21

Family

ID=67105990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518994A Pending JP2021527137A (ja) 2018-06-13 2019-06-13 Rpn11を標的化するための二機能性分子

Country Status (7)

Country Link
US (1) US11925690B2 (cg-RX-API-DMAC10.html)
EP (1) EP3807272A1 (cg-RX-API-DMAC10.html)
JP (1) JP2021527137A (cg-RX-API-DMAC10.html)
KR (1) KR20210021016A (cg-RX-API-DMAC10.html)
CN (1) CN112533918A (cg-RX-API-DMAC10.html)
CA (1) CA3103185A1 (cg-RX-API-DMAC10.html)
WO (1) WO2019238817A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL303717A (en) 2020-12-18 2023-08-01 Amphista Therapeutics Ltd Novel bifunctional molecules for targeted protein degradation
AU2022362494A1 (en) * 2021-10-14 2024-05-23 Cullgen (Shanghai), Inc. Modified proteins and protein degraders
CN114959036A (zh) * 2022-06-07 2022-08-30 北京大学 Rpn11标记物在检测骨髓瘤及其患病风险、预后分析及治疗药物中的应用
JP2025525347A (ja) 2022-06-16 2025-08-05 アンフィスタ セラピューティクス リミテッド 標的タンパク質分解のための新規の二官能性分子
WO2023242598A1 (en) 2022-06-16 2023-12-21 Amphista Therapeutics Limited Bifunctional molecules for targeted protein degradation
AU2023343029A1 (en) 2022-09-13 2025-03-27 Amphista Therapeutics Limited Compounds for targeted protein degradation
AU2023358062A1 (en) 2022-10-07 2025-03-20 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
AU2024395784A1 (en) 2023-12-07 2026-06-11 Pfizer Inc. Biphenyl and phenylpyridine compounds as inhibitors of kat2a and/or kat2b
GB202319256D0 (en) 2023-12-15 2024-01-31 Amphista Therapeutics Ltd Novel compounds for targeted protein degradation
WO2026088071A1 (en) 2024-10-23 2026-04-30 Pfizer Inc. Substituted fused heteroaryl lactam compounds
WO2026154417A1 (en) 2025-01-17 2026-07-23 Pfizer Inc. Fused heterocyclic amide/sulfonamide compounds as agonists of the calcitonin/amylin receptors for the treatment of obesity
WO2026159633A1 (en) 2025-01-24 2026-07-30 Pfizer Inc. 4-(2-(dimethylamino)-2-oxoethyl)-3-methyl-5-oxo-2,3,4,5-tetrahydrobenzofuro[2,3-f][1,4]oxazepine-3-carboxamide compounds and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1993020094A1 (en) 1992-03-27 1993-10-14 Abbott Laboratories Haptens, tracers, immunogens and antibodies for quinoline
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
AU2001295041A1 (en) * 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
ZA200800314B (en) 2005-06-29 2009-09-30 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
US8552048B2 (en) 2006-12-26 2013-10-08 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
WO2009041072A1 (ja) * 2007-09-27 2009-04-02 Kowa Company, Ltd. テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
EP2649099A4 (en) 2010-12-07 2016-10-19 Univ Yale SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS
EP2710119A4 (en) 2011-05-17 2015-02-18 Cleave Biosciences Inc COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION
KR102438072B1 (ko) 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
EP2994135B1 (en) 2013-05-08 2021-10-06 The Johns Hopkins University Novel bis-benzylidine piperidinone proteasome inhibitor with anticancer activity
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
CA2988414C (en) * 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
JP6954619B2 (ja) 2015-06-19 2021-10-27 学校法人東京理科大学 タンパク質分解誘導タグ及びその用途
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
US10005735B2 (en) 2015-08-17 2018-06-26 California Institute Of Technology Inhibitors of RPN11
GB201516243D0 (en) * 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
AU2017253560B2 (en) * 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN110035775A (zh) 2016-11-15 2019-07-19 学校法人东京理科大学 Ras蛋白分解诱导分子和药物组合物
CN112236172A (zh) 2018-01-30 2021-01-15 福宏治疗公司 用于治疗病症的方法和化合物
US11702402B2 (en) 2018-02-23 2023-07-18 Dana-Farber Cancer Institute, Inc. Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof
JP7472026B2 (ja) 2018-02-23 2024-04-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 選択的なタンパク質分解を誘導するための低分子およびその使用法
CA3095912A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
WO2020146561A1 (en) 2019-01-09 2020-07-16 Dana-Farber Cancer Institute, Inc. Dot1l degraders and uses thereof

Similar Documents

Publication Publication Date Title
JP2021533181A5 (cg-RX-API-DMAC10.html)
JP7449864B2 (ja) エバンスブルー誘導体の化学結合体ならびに前立腺癌を標的とするための放射線療法および造影剤としてのその使用
CN101657454B (zh) 18f-标记的叶酸类
JP2011518194A5 (cg-RX-API-DMAC10.html)
JP2022537773A5 (cg-RX-API-DMAC10.html)
Jacobson et al. A rapid and simple one-step F-18 labeling of peptides
US11401376B2 (en) Chemical compounds for coating of nanostructures
RS56171B1 (sr) Derivati stirilpiridina i njihova upotreba za vezivanje i imidžing amiloidnih plakova
RS55855B1 (sr) Derivati piridina i pirazina za tretman hronične opstruktivne bolesti pluća
Gai et al. Synthesis and evaluation of new bifunctional chelators with phosphonic acid arms for gallium-68 based PET imaging in melanoma
KR20160074683A (ko) 18f-표지된 폴레이트
JP2007511494A5 (cg-RX-API-DMAC10.html)
CN102802672B (zh) 髓鞘碱性蛋白的成像
US20230348378A1 (en) Small molecule albumin binders
CN117836013A (zh) 结合至成纤维细胞活化蛋白(fap)的放射性示踪剂和治疗剂
JP2014501714A (ja) コンジュゲートおよび分子イメージングにおけるそれらの用途
JP5693950B2 (ja) 18f標識葉酸
US20040053911A1 (en) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them
AU2014205481A1 (en) Therapeutic indications of kinase inhibitors
CN102558091B (zh) 一种苯并噻唑类衍生物及其用途
Basuli et al. A first synthesis of 18F‐radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity
KR100186799B1 (ko) 단백질에 금속 이온을 부착하기 위한 킬레이트제
Wang et al. Rational design of pyridinium styryl derivatives as PET tracers for cardiac amyloidosis imaging
Kimura et al. Radiosynthesis of novel pitavastatin derivative ([18F] PTV‐F1) as a tracer for hepatic OATP using a one‐pot synthetic procedure
Kogler et al. Synthesis and preclinical evaluation of FAP-targeting radiotracers for PET and optical imaging